{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:31:19Z","timestamp":1761093079074,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.urolonc.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T07:52:11Z","timestamp":1519977131000},"page":"242.e1-242.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-9975","authenticated-orcid":false,"given":"Johannes","family":"Falke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Hulsbergen-van de Kaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Maj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.01.016_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ni1116","article-title":"Toll-like receptors in the pathogenesis of human disease","volume":"5","author":"Cook","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib6","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.juro.2007.01.112","article-title":"Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder","volume":"177","author":"Smith","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2008-0097","article-title":"The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy","volume":"13","author":"Smits","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2018.01.016_bib8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1084\/jem.20070021","article-title":"Tumoricidal activity of TLR7\/8-activated inflammatory dendritic cells","volume":"204","author":"Stary","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.urolonc.2018.01.016_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/djg016","article-title":"Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod","volume":"95","author":"Schon","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2018.01.016_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/1744666X.2015.983082","article-title":"Immunological basis in the pathogenesis and treatment of bladder cancer","volume":"11","author":"Thompson","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study","volume":"47","author":"Geisse","year":"2002","journal-title":"J.Am.Acad.Dermatol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eururo.2012.02.052","article-title":"Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents","volume":"62","author":"Alnajjar","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1464-410X.2010.10055.x","article-title":"Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs","volume":"108","author":"Arentsen","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.01.016_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1442-2042.2010.02503.x","article-title":"Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer","volume":"17","author":"Hayashi","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.juro.2012.11.150","article-title":"Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer","volume":"189","author":"Falke","year":"2013","journal-title":"J. Urol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clgc.2014.12.010","article-title":"Pharmacokinetic, pharmacodynamic, and activity evaluation of TMX-101 in a multicenter phase 1 study in patients with papillary non-muscle-invasive bladder cancer","volume":"13","author":"Arends","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2018.01.016_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2016.09.006","article-title":"A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib20","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/bc900054q","article-title":"Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates","volume":"20","author":"Chan","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.urolonc.2018.01.016_bib21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1684\/ejd.2013.2155","article-title":"Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects","volume":"23","author":"Crain","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/sj.bjc.6690741","article-title":"Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model","volume":"81","author":"Xiao","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2018.01.016_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/jid.2011.247","article-title":"Immunomodulation by imiquimod in patients with high-risk primary melanoma","volume":"132","author":"Narayan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2010.12.340","article-title":"Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial","volume":"121","author":"Terlou","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2018.01.016_bib25","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.clgc.2015.01.005","article-title":"Development of predictive value of urinary cytokine profile induced during intravesical bacillus Calmette-Guerin instillations for bladder cancer","volume":"13","author":"Rigaud","year":"2015","journal-title":"Clin Genitourin Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:12:16Z","timestamp":1761041536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918300383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1078143918300383"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.01.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}